What is the role of Identification (ID), Investigation, and Intervention in post-fracture care?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 26, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The 3 "I's" (Identification, Investigation, and Intervention) are crucial components of post-fracture care, with the Fracture Liaison Service (FLS) model being the most effective organisational structure for risk evaluation and treatment initiation, as evidenced by a systematic review and meta-analysis 1. The Identification step involves systematically evaluating patients aged 50 years and over with a recent fracture for the risk of subsequent fractures, which can be achieved through a dedicated coordinator who takes care of all aspects of the process.

  • This coordinator, often a well-educated nurse, works under the supervision of an orthopaedic surgeon, an endocrinologist, or a rheumatologist to identify elderly patients with a recent fracture in the hospital.
  • The Investigation phase encompasses diagnostic investigations, such as bone mineral density testing, fall risk evaluation, and laboratory tests to identify secondary causes of osteoporosis.
  • The Intervention component involves starting interventions, providing adequate medical information to patients and primary care physicians (PCPs), and implementing evidence-based treatments to reduce future fracture risk. Key aspects of the Intervention include:
  • Providing specific patient education
  • Alerting the PCP by means of a discharge letter containing medical information on the fracture of the patient
  • Initiating osteoporosis treatment, with studies showing that a nominated coordinator significantly improves the implementation of osteoporosis treatment after a fragility fracture 1. By applying the 3 "I's" framework through an FLS model, healthcare systems can significantly reduce the burden of secondary fractures and improve patient outcomes, with a nominated coordinator improving the implementation of osteoporosis treatment after a fragility fracture, resulting in 45% of patients receiving appropriate management, compared to 26% in the control group 1.

From the FDA Drug Label

The FDA drug label does not answer the question.

From the Research

Role of Identification (ID) in Post-Fracture Care

  • Identification of patients with osteoporosis who have been hospitalized for major fractures is crucial in post-fracture care 2
  • Patients diagnosed with osteoporosis can be identified from national health insurance research databases, allowing for follow-up and analysis of survival outcomes 2

Role of Investigation in Post-Fracture Care

  • Investigation of the efficacy and safety of medications used to prevent fractures is essential in post-fracture care 3, 4, 5, 6
  • Studies have investigated the antifracture efficacy of various medications, including bisphosphonates, denosumab, and teriparatide, in preventing spine, nonspine, and hip fractures 3, 4, 5
  • Investigation of the long-term safety of these medications has also been conducted, with findings indicating that the safety profile of most available drugs for the treatment of osteoporosis is well defined 6

Role of Intervention in Post-Fracture Care

  • Intervention with bisphosphonates, such as zoledronic acid, ibandronate, and alendronate, has been shown to reduce post-fracture mortality among patients with osteoporosis 2
  • Intervention with risedronate gastro-resistant has been shown to have a lower incidence of fractures compared to other oral bisphosphonates 5
  • The choice of intervention should consider the balance between the beneficial effects of treatment, the probability of adverse effects, and costs, particularly in patients at low risk of fracture 6
  • A "drug holiday" may be considered after 5-10 years of bisphosphonate treatment, depending on fracture risk and pharmacokinetics of the bisphosphonate used 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Long-term use of bisphosphonates in osteoporosis.

The Journal of clinical endocrinology and metabolism, 2010

Research

Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2022

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.